RareSight AG is now Vivarus Diagnostics AG

RareSight AG has been renamed Vivarus Diagnostics AG. The change was entered in the Swiss commercial register on 28 August 2026.

We've renamed to Vivarus Diagnostics AG; same company, same team, same vision, with a name that better reflects what we're building.

What this means in practice

This is a change of name only. Vivarus Diagnostics AG is the same legal entity as RareSight AG, with the same founders, the same ownership and the same registered address. Existing agreements and contractual relationships continue unchanged, and no action is needed from our partners.

Where to find us

Our website is now at vivarus.com, and our email addresses have moved to @vivarus.com. Messages sent to our previous rare-sight.com addresses will continue to reach us, so existing correspondence is unaffected.

What we are building

Our mission is unchanged: to help clinicians recognise rare diseases earlier, reduce diagnostic uncertainty, and shorten the diagnostic journey for patients living with a rare condition.

There is a great deal still to do, and we will continue to share our progress here as our clinical validation and regulatory work advances.

Vivarus Diagnostics is in development and is not CE-marked. It is not available for clinical use.

For questions about the name change, contact us at info@vivarus.com.